Daner Wealth Management LLC Acquires New Shares in Eli Lilly and Company $LLY

Daner Wealth Management LLC bought a new stake in Eli Lilly and Company (NYSE:LLY) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 724 shares of the company’s stock, valued at approximately $564,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Brighton Jones LLC grew its stake in shares of Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares in the last quarter. Covestor Ltd grew its position in Eli Lilly and Company by 24.9% during the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock worth $352,000 after acquiring an additional 85 shares during the last quarter. Kaufman Rossin Wealth LLC acquired a new position in Eli Lilly and Company in the 1st quarter worth about $242,000. Finally, Donoghue Forlines LLC bought a new position in Eli Lilly and Company in the first quarter valued at about $2,261,000. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on LLY. Morgan Stanley boosted their price target on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a report on Monday, November 24th. Leerink Partnrs upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Monday, November 10th. Leerink Partners raised shares of Eli Lilly and Company from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $886.00 to $1,104.00 in a research report on Monday, November 10th. National Bankshares set a $1,286.00 price target on shares of Eli Lilly and Company in a research note on Monday, December 1st. Finally, HSBC upped their price objective on shares of Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $1,087.32.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,009.26 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The firm has a fifty day simple moving average of $918.84 and a two-hundred day simple moving average of $809.74. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,111.99. The firm has a market capitalization of $954.13 billion, a PE ratio of 49.38, a price-to-earnings-growth ratio of 1.12 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company’s quarterly revenue was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s payout ratio is presently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.